Amphetamine

The onset of oral amphetamine is gradual and workmanlike. Over thirty to sixty minutes, there is a steadily building sense of mental clarity -- like a fog lifting that you didn't realize was there. The first thing most people notice is motivational: tasks that felt tedious suddenly seem approachable, even interesting. Attention narrows and locks on. There is a quiet confidence, a sense that you can handle whatever is in front of you. The euphoria at therapeutic doses is subtle -- less a rush and more a clean, optimistic hum in the background. Many people on r/ADHD describe their first properly dosed experience as "this must be what normal feels like."

As the drug reaches its peak (roughly two to four hours in), the experience is dominated by productive focus. Thoughts come quickly and in orderly sequence. Conversation flows more easily. Physical energy is elevated but controlled -- endurance without jitteriness, at least at moderate doses. Appetite vanishes almost completely. There is a mild mood elevation that makes social interaction more enjoyable and physical work less burdensome. The body feels light, capable, ready.

The physical side effects build in parallel. Heart rate climbs moderately. The mouth goes dry and stays dry regardless of how much water you drink. Jaw clenching is common. Peripheral vasoconstriction makes hands and feet feel cold. At therapeutic doses, these effects are tolerable background noise. At higher recreational doses, the stimulation crosses a line: the heartbeat becomes uncomfortably prominent, jaw clenching intensifies, and that productive focus can narrow into an obsessive fixation on something that doesn't actually matter -- the classic "spent four hours reorganizing desktop icons" phenomenon that experienced users joke about but that genuinely reflects how supratherapeutic dopamine distorts priority assessment.

One of the most discussed effects in community forums is emotional flattening. The drug provides energy and focus but can compress emotional range, making you efficient but robotic. People on r/ADHD frequently report that prescribed amphetamine helps them function but costs them spontaneity or emotional warmth -- a trade-off many consider worthwhile but others find distressing over time.

The duration of oral amphetamine is long -- typically six to ten hours, with extended-release formulations stretching to twelve or more. The descent from peak is gradual, reducing compulsive redosing compared to cocaine. However, as the drug wears off, there is a characteristic rebound: energy drains, motivation drops, and heavy, irritable fatigue settles in.

The crash can last twelve to twenty-four hours -- exhaustion, increased sleep need, depressed mood, difficulty concentrating. Heavy or prolonged use intensifies this considerably. Community members consistently call the crash the most underestimated aspect of amphetamine use: "the high borrows happiness from tomorrow" is a phrase that recurs across drug forums, and it captures the pharmacology accurately. The monoamine stores that were force-released need time to replenish.

Transporter Reversal: Not a Reuptake Inhibitor

Amphetamine's mechanism is fundamentally different from reuptake inhibitors like cocaine or methylphenidate. Where those drugs block monoamine transporters from the outside, amphetamine is a substrate-type releaser -- it is recognized by the dopamine transporter (DAT) and norepinephrine transporter (NET) as a structural analogue of natural substrates and gets actively transported into the presynaptic terminal. Once inside, it triggers a signaling cascade that reverses transporter function, pumping dopamine and norepinephrine out of the neuron into the synaptic cleft. This is not passive blockade; it is active, forced release.

TAAR1: The Intracellular Trigger

The discovery of trace amine-associated receptor 1 (TAAR1) was a breakthrough in understanding how amphetamine works at the molecular level. TAAR1 is an intracellular G-protein-coupled receptor on the cytoplasmic face of presynaptic terminals. When amphetamine binds TAAR1, it activates Gs and G13 signaling pathways, elevating cyclic AMP and activating protein kinase A (PKA) and protein kinase C (PKC). These kinases phosphorylate DAT, causing it to reverse direction -- the molecular event producing amphetamine-induced dopamine efflux. TAAR1-knockout mice show dramatically exaggerated locomotor responses to amphetamine, confirming TAAR1 normally acts as a brake on stimulant sensitivity. A 2023 Nature paper revealing the crystal structure of TAAR1 bound to methamphetamine showed these drugs fit into a specific hydrophobic pocket on transmembrane helices TM5 and TM6.

One nuance: amphetamine shows nanomolar potency at rodent TAAR1 but only micromolar potency at human TAAR1, meaning rodent studies may overestimate this receptor's contribution to the human experience.

VMAT2 Disruption: Emptying the Reserves

Inside the terminal, amphetamine attacks vesicular monoamine transporter 2 (VMAT2), which packages dopamine into synaptic vesicles for controlled release. As a weak base, amphetamine dissipates the vesicular proton gradient VMAT2 depends on, and directly competes with dopamine for binding sites. The result is massive redistribution of dopamine from vesicular stores into the cytoplasm, where it becomes available for reverse transport through DAT. This is why the crash feels so thorough -- the vesicles that buffer dopamine release have been emptied.

Norepinephrine, Serotonin, and MAO

Amphetamine's effects on the norepinephrine transporter (NET) are roughly equipotent to its effects on DAT and drive much of the physiological profile: increased heart rate, elevated blood pressure, bronchodilation, and alertness. Its affinity for theserotonin transporter (SERT) is weak compared to methamphetamine or MDMA, partially explaining why amphetamine produces less empathogenic warmth and lower serotonergic neurotoxicity risk. At higher doses, weakMAO inhibition slows breakdown of cytoplasmic monoamines, further amplifying the signal.

The Dose-Dependent Switch

At therapeutic doses (5-30 mg), amphetamine enhances prefrontal cortex dopamine and norepinephrine tone, sharpening attention and impulse control. At supratherapeutic doses, massive dopamine release in the nucleus accumbens produces intense euphoria, reinforcement, and the neurochemical conditions for addiction. This transition is a gradient, not a cliff edge -- where a person falls depends on dose, genetics, tolerance, and route of administration.

Amphetamine was first synthesized on January 18, 1887, by Romanian chemist Lazar Edeleanu at the University of Berlin. He called it "phenylisopropylamine," documented its chemical properties, and moved on. The molecule sat forgotten for over four decades.

Its pharmacological resurrection came through Gordon Alles, a Los Angeles biochemist hunting for a cheaper alternative to ephedrine. On June 3, 1929, Alles had 50 mg of amphetamine sulfate injected and experienced profound wakefulness, euphoria, and a "feeling of well-being" far beyond what any bronchodilator should produce. He patented his findings and licensed them to Smith, Kline & French (SKF).

SKF launched the Benzedrine inhaler in 1932 as an over-the-counter decongestant. Users quickly discovered they preferred the stimulant effects to the clear sinuses -- students cracked open the inhalers and ate the amphetamine-soaked cotton strips, truck drivers used them for marathon hauls. Benzedrine tablets followed in 1937 for narcolepsy and depression.

World War II transformed amphetamine into a military-industrial commodity. The US distributed Benzedrine to pilots, submariners, and infantry; Britain did the same; Germany issued methamphetamine as Pervitin; Japan manufactured Philopon. By war's end, an estimated 16 million young Americans had been exposed during service, and over half a million civilians were already using it.

The postwar years brought an epidemic. Pharmaceutical companies marketed amphetamine for depression, obesity, fatigue, and "housewife syndrome." By 1962, American companies produced roughly eight billion tablets per year. The 1960s speed epidemic led to the Controlled Substances Act of 1970, placing amphetamine on Schedule II and slashing production quotas by 80-90%.

The molecule found new life in the 1990s ADHD treatment boom. Adderall was approved in 1996, Vyvanse in 2007. Today, the tension between amphetamine's genuine therapeutic value and its abuse potential remains one of the defining debates in psychopharmacology.